Logo BSU

Please use this identifier to cite or link to this item: https://elib.bsu.by/handle/123456789/288376
Title: RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia
Authors: Grinev, V.V.
Barneh, F.
Ilyushonak, I.M.
Nakjang, S.
Smink, J.
van Oort, A.
Clough, R.
Seyani, M.
McNeill, H.
Reza, M.
Martinez-Soria, N.
Assi, S.
Assi, T.V.
Bonifer, C.
Heidenreich, O.
Keywords: ЭБ БГУ::ЕСТЕСТВЕННЫЕ И ТОЧНЫЕ НАУКИ::Биология
ЭБ БГУ::ТЕХНИЧЕСКИЕ И ПРИКЛАДНЫЕ НАУКИ. ОТРАСЛИ ЭКОНОМИКИ::Медицина и здравоохранение
Issue Date: 2021
Publisher: Nature Research
Citation: Nat Commun 2021;12(1)
Abstract: The fusion oncogene RUNX1/RUNX1T1 encodes an aberrant transcription factor, which plays a key role in the initiation and maintenance of acute myeloid leukemia. Here we show that the RUNX1/RUNX1T1 oncogene is a regulator of alternative RNA splicing in leukemic cells. The comprehensive analysis of RUNX1/RUNX1T1-associated splicing events identifies two principal mechanisms that underlie the differential production of RNA isoforms: (i) RUNX1/RUNX1T1-mediated regulation of alternative transcription start site selection, and (ii) direct or indirect control of the expression of genes encoding splicing factors. The first mechanism leads to the expression of RNA isoforms with alternative structure of the 5’-UTR regions. The second mechanism generates alternative transcripts with new junctions between internal cassettes and constitutive exons. We also show that RUNX1/RUNX1T1-mediated differential splicing affects several functional groups of genes and produces proteins with unique conserved domain structures. In summary, this study reveals alternative splicing as an important component of transcriptome re-organization in leukemia by an aberrant transcriptional regulator
URI: https://elib.bsu.by/handle/123456789/288376
DOI: 10.1038/s41467-020-20848-z
Scopus: 85099760145
Sponsorship: The authors thank Dr. Aliaksandra Radzisheuskaya (Cell Biology Program and Center for Epigenetics, Memorial Sloan Kettering Cancer Center, New York, USA) for carefully reading and improving the manuscript, Dr. Petr Nazarov (Luxembourg Institute of Health, Strassen, Luxembourg) for excellent practical ideas with independent component analysis, Dr. Paul Boutz (Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA) for comprehensive discussion of the pipeline and tips on identifying retained introns, and Dr. Thomas Langer (University of Cologne, Cologne, Germany) for providing us with original anti-PARL antibodies. Research in the V.V.G. laboratory was supported in part by the Ministry of Education of the Republic of Belarus, grant #3.08.3 (947/54, 469/54). O.H. is supported by grants from Cancer Research UK (C27943/A12788), Bloodwise (15005), Kay Kendall Leukemia Fund (KKL1142), the North of England Children’s Cancer Fund and KIKA (329). C.B. is supported by Bloodwise (15001).
Licence: info:eu-repo/semantics/openAccess
Appears in Collections:Статьи биологического факультета

Files in This Item:
File Description SizeFormat 
1-s2.0-S2589965121000155-main (1).pdf1,54 MBAdobe PDFView/Open
Show full item record Google Scholar



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.